Shots:

• The approval is based on its non-inferiority data consisting of its PK- efficacy- safety- immunogenicity data with the reference product in analytical- preclinical and clinical data trials
• Fresenius Kabi has a portfolio consisting of generic drugs- infusion therapies- biosimilars- and clinical nutrition products focusing on multiple therapy areas
• Idacio (adalimumab- biosimilar) is a mAb and is indicated for Rheumatoid arthritis (RA)- Juvenile Idiopathic Arthritis- Axial Spondyloarthritis- psoriatic arthritis- plaque psoriasis- adult & pediatric Crohn’s disease and ulcerative colitis

Ref: Fresenius Kabi | Image: Behance